Vivos Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RDGL research report →
Companywww.radiogel.com
Vivos Inc. , a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals.
- CEO
- Michael K. Korenko
- IPO
- 1998
- Employees
- 1
- HQ
- Kennewick, WA, US
Price Chart
Valuation
- Market Cap
- $32.29M
- P/E
- -9.05
- P/S
- 415.60
- P/B
- 11.46
- EV/EBITDA
- -10.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -275.58%
- Op Margin
- -3664.15%
- Net Margin
- -4396.28%
- ROE
- -148.20%
- ROIC
- -101.43%
Growth & Income
- Revenue
- $68.38K · 144.25%
- Net Income
- $-3,066,017 · -5.36%
- EPS
- $-0.01 · 4.23%
- Op Income
- $-3,165,047
- FCF YoY
- -28.32%
Performance & Tape
- 52W High
- $0.15
- 52W Low
- $0.04
- 50D MA
- $0.08
- 200D MA
- $0.08
- Beta
- -0.76
- Avg Volume
- 1.26M
Get TickerSpark's AI analysis on RDGL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Korenko Michael K | buy | 150,000 |
| Sep 15, 25 | Weeks Brad Allan | other | 0 |
| Nov 18, 27 | Weeks Brad Allan | other | 500,000 |
| Dec 31, 25 | Korenko Michael K | buy | 200,000 |
| Dec 2, 25 | Korenko Michael K | buy | 100,000 |
| Nov 20, 25 | Korenko Michael K | buy | 100,000 |
| Aug 14, 25 | Korenko Michael K | buy | 100,000 |
| Oct 28, 24 | Korenko Michael K | buy | 50,000 |
| Sep 30, 24 | Korenko Michael K | buy | 50,000 |
| Aug 13, 24 | Korenko Michael K | buy | 50,000 |
Our RDGL Coverage
We haven't published any research on RDGL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RDGL Report →